ERBB2 and breast cancer: However, approximately 60% of hormone receptor (HR)+ /HER2− BC and 40% of triple-negative BC (TNBC) cases exhibit HER2 expression classified as score 1 + or 2 + without gene amplification (Fig. 1) [74].